Tianshili: Shubili tablets are evaluated for consistency by generics.

Shubley tablets are used for schizophrenia, have a certain effect on depressive symptoms, other uses have anti-nausea, for the national essential drugs, and into the national health insurance directory (Class A).
the drug was submitted to the State Drug Administration on August 12, 2019, and was accepted on August 19, 2019.
as of this announcement day, nearly 100 enterprises in China have obtained the approval number of Shubili tablets, the main production enterprises in addition to Jiangsu Diyi, as well as Enhua Pharmaceuticals, Guangdong Peti Pharmaceuticals and Shanghai Pharmaceutical Xinyi Pharmaceutical Sinyi Pharmaceutical Sein. according to the
, the annual sales of urban public hospitals in 2019 were 41.68 million yuan (61.27 percent of the annual sales of urban public hospitals), with an annual growth rate of 24.77 percent in 2019.
as of the date of announcement, Jiangsu Tiyi for the drug consistency evaluation has invested about 5.56 million yuan in research and development costs.
.